![IJMS | Free Full-Text | Generation and Characterization of a Polyclonal Human Reference Antibody to Measure Anti-Drug Antibody Titers in Patients with Fabry Disease IJMS | Free Full-Text | Generation and Characterization of a Polyclonal Human Reference Antibody to Measure Anti-Drug Antibody Titers in Patients with Fabry Disease](https://www.mdpi.com/ijms/ijms-22-02680/article_deploy/html/images/ijms-22-02680-g001.png)
IJMS | Free Full-Text | Generation and Characterization of a Polyclonal Human Reference Antibody to Measure Anti-Drug Antibody Titers in Patients with Fabry Disease
![Sensitive assay design for detection of anti-drug antibodies to biotherapeutics that lack an immunoglobulin Fc domain | Scientific Reports Sensitive assay design for detection of anti-drug antibodies to biotherapeutics that lack an immunoglobulin Fc domain | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-95055-x/MediaObjects/41598_2021_95055_Fig1_HTML.png)
Sensitive assay design for detection of anti-drug antibodies to biotherapeutics that lack an immunoglobulin Fc domain | Scientific Reports
![Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1 | Scientific Reports Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1 | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-07997-5/MediaObjects/41598_2022_7997_Fig1_HTML.png)
Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1 | Scientific Reports
![Assay signal as an alternative to titer for assessment of magnitude of an antidrug antibody response | Bioanalysis Assay signal as an alternative to titer for assessment of magnitude of an antidrug antibody response | Bioanalysis](https://www.future-science.com/cms/10.4155/bio-2017-0185/asset/images/medium/figure3.gif)
Assay signal as an alternative to titer for assessment of magnitude of an antidrug antibody response | Bioanalysis
![Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine - James M Martinez, Nada Hindiyeh, Greg Anglin, Kavita Kalidas, Michael E Hodsdon, William Kielbasa, Brian A Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine - James M Martinez, Nada Hindiyeh, Greg Anglin, Kavita Kalidas, Michael E Hodsdon, William Kielbasa, Brian A](https://journals.sagepub.com/cms/10.1177/0333102420920642/asset/images/large/10.1177_0333102420920642-fig2.jpeg)
Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine - James M Martinez, Nada Hindiyeh, Greg Anglin, Kavita Kalidas, Michael E Hodsdon, William Kielbasa, Brian A
![Boxplot of positive ADA titer results by visit and treatment (safety... | Download Scientific Diagram Boxplot of positive ADA titer results by visit and treatment (safety... | Download Scientific Diagram](https://www.researchgate.net/publication/355626735/figure/fig2/AS:1083310738550784@1635292815079/Boxplot-of-positive-ADA-titer-results-by-visit-and-treatment-safety-population-in.png)
Boxplot of positive ADA titer results by visit and treatment (safety... | Download Scientific Diagram
![Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium | The AAPS Journal Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium | The AAPS Journal](https://media.springernature.com/lw812/springer-static/esm/art%3A10.1208%2Fs12248-022-00728-8/MediaObjects/12248_2022_728_Fig5_ESM.png)
Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium | The AAPS Journal
![Drug Concentrations and Anti-drug Antibodies Influence in Response to Adalimumab: Results from the BioEfficacySpA Clinical Trial - ACR Meeting Abstracts Drug Concentrations and Anti-drug Antibodies Influence in Response to Adalimumab: Results from the BioEfficacySpA Clinical Trial - ACR Meeting Abstracts](https://acrabstracts.org/wp-content/uploads/2019/08/GTUOHVCE-699983-1-ANY.jpg)
Drug Concentrations and Anti-drug Antibodies Influence in Response to Adalimumab: Results from the BioEfficacySpA Clinical Trial - ACR Meeting Abstracts
![Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies - ScienceDirect Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0022175920300338-gr4.jpg)
Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies - ScienceDirect
![Effect of maximum ADA titer results on ACR20 response rate and mean... | Download Scientific Diagram Effect of maximum ADA titer results on ACR20 response rate and mean... | Download Scientific Diagram](https://www.researchgate.net/publication/337920685/figure/fig4/AS:963130708484098@1606639663358/Effect-of-maximum-ADA-titer-results-on-ACR20-response-rate-and-mean-DAS28-CRP-at-week-24.png)
Effect of maximum ADA titer results on ACR20 response rate and mean... | Download Scientific Diagram
![A systematic examination of anti-drug antibody titer estimation: Applied recommendations - ScienceDirect A systematic examination of anti-drug antibody titer estimation: Applied recommendations - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0022175923001515-gr1.jpg)
A systematic examination of anti-drug antibody titer estimation: Applied recommendations - ScienceDirect
![Heat pre-treatment can abolish anti-drug antibody interference in ligand binding pharmacokinetic assays | AAPS Open | Full Text Heat pre-treatment can abolish anti-drug antibody interference in ligand binding pharmacokinetic assays | AAPS Open | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs41120-022-00056-3/MediaObjects/41120_2022_56_Fig3_HTML.png)
Heat pre-treatment can abolish anti-drug antibody interference in ligand binding pharmacokinetic assays | AAPS Open | Full Text
![Assay signal as an alternative to titer for assessment of magnitude of an antidrug antibody response | Bioanalysis Assay signal as an alternative to titer for assessment of magnitude of an antidrug antibody response | Bioanalysis](https://www.future-science.com/cms/10.4155/bio-2017-0185/asset/images/medium/figure2.gif)
Assay signal as an alternative to titer for assessment of magnitude of an antidrug antibody response | Bioanalysis
![Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium | The AAPS Journal Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium | The AAPS Journal](https://media.springernature.com/m685/springer-static/image/art%3A10.1208%2Fs12248-022-00728-8/MediaObjects/12248_2022_728_Figa_HTML.png)
Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium | The AAPS Journal
![ADA titer analyses. (a) Atezolizumab concentration by ADA titer and (b)... | Download Scientific Diagram ADA titer analyses. (a) Atezolizumab concentration by ADA titer and (b)... | Download Scientific Diagram](https://www.researchgate.net/publication/354139205/figure/fig4/AS:11431281179869232@1691419208094/ADA-titer-analyses-a-Atezolizumab-concentration-by-ADA-titer-and-b-overall-survival.png)
ADA titer analyses. (a) Atezolizumab concentration by ADA titer and (b)... | Download Scientific Diagram
![Antibodies against recombinant enzyme in the treatment of Fabry disease: Now you see them, now you don't: Molecular Therapy Methods & Clinical Development Antibodies against recombinant enzyme in the treatment of Fabry disease: Now you see them, now you don't: Molecular Therapy Methods & Clinical Development](https://www.cell.com/cms/attachment/54388282-adf8-410d-a893-0d6e37bdd4ad/gr1_lrg.jpg)
Antibodies against recombinant enzyme in the treatment of Fabry disease: Now you see them, now you don't: Molecular Therapy Methods & Clinical Development
![Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium | The AAPS Journal Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium | The AAPS Journal](https://media.springernature.com/lw812/springer-static/esm/art%3A10.1208%2Fs12248-022-00728-8/MediaObjects/12248_2022_728_Fig6_ESM.png)
Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium | The AAPS Journal
![Heat pre-treatment can abolish anti-drug antibody interference in ligand binding pharmacokinetic assays | AAPS Open | Full Text Heat pre-treatment can abolish anti-drug antibody interference in ligand binding pharmacokinetic assays | AAPS Open | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs41120-022-00056-3/MediaObjects/41120_2022_56_Fig4_HTML.png)